Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, has appointed Eric Luthi as Chief Business Officer. In this newly created role, Luthi brings over 25 years of experience in life sciences and will lead corporate and business development initiatives at Koneksa.
 
“We’re thrilled to welcome Eric to lead our business development team,” said Chris Benko, CEO and Co-Founder of Koneksa. “With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotal role in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations. His leadership will be invaluable as we empower biopharma companies to utilize digital biomarkers to accelerate clinical trials and unlock critical data insights.”
 
“I’m honored to join Koneksa as we continue to advance the role of evidence-based digital biomarkers in clinical trials to accelerate decision making and improve patient outcomes,” said Luthi.

Experience 

Prior to joining Koneksa, Luthi served as Chief Commercial Officer at Evergreen Therapeutics, where he established the commercial function and led the development of the launch strategy for the company’s diagnostic radiopharmaceutical.
 
Luthi has held commercial leadership roles in large and small pharmaceutical companies in the US, Canada, and Switzerland. Over his 20-year tenure at Merck & Co., Inc., he helped to integrate research and commercial strategies in a number of key therapeutic areas for the company and, working closely with R&D leadership, was the commercial lead for cardiovascular products in clinical development. As head of Digital and Commercial Operations for Merck’s subsidiary in Canada, he was responsible for enhancing customer engagement and driving revenue growth by integrating digital and traditional marketing efforts.
 
He holds a Bachelor of Science degree with a double major in Biology and Psychology from Muhlenberg College.